Abstract
Compared with placebo, Drotecogin alpha (activated) offers no mortality benefit at either 28 or 90 days in critically ill adults with septic shock.
Level of evidence: 1B (well designed RCT)
You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026
Filter Results
Select search scope: search across all journals or within the current journal
Search this journal
Enter search terms…
/